|
FOR US RESIDENTS ONLY
| NON US RESIDENTS
|
Novartis Pharmaceuticals Corporation, a global leader in Philadelphia Chromosome-positive Chronic Myeloid Leukemia (Ph+ CML) therapy, has been working with healthcare professionals and patients worldwide to help improve the treatment of Ph+ CML.
Use of this website is governed by the
Terms of Use
and
Privacy Statement.
© 2010 Novartis Pharmaceuticals Corporation. All Rights Reserved.
|